UBIO ETF Composition
General Overview
The investment seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the NASDAQ Biotechnology Index® (the index). The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
| Sector & Industry | Financial Services / Asset Management - Leveraged |
| IPO date | June 22, 2015 |
UBIO Latest News
|
|
|
|
|
|
|
|
|
|
| Other Identifiers | |
|---|---|
| CIK | 0001174610 |
| ISIN | None |
| CUSIP | None |
| Open | 17.97 |
| Previous Close | 17.7652 |
| Volume | 34.71 Thou. |
| Average Volume | 0 |
| Day’s Range | 17.43 – 19.24 |
| 52 Week Range | 13.13-34.8 |
| MA (50) | 17.7652 |
| MA (200) | 17.7652 |
| Market Cap | 15.09 Mil. |
| Shares Out. | 849.3 Thou. |
| Earnings Date | |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
